hotspot -WSS

hotspot

author：hotspot 2025-10-01 20:16:36 - browse：76432

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： STAT letters to the editor on burnt

WSS

Radiology is caught between AI's potential and concern for patients

Driven by the pandemic, applicants flood public health schools

Stanford president's case begs question: Who takes blame?

Tesla recalling nearly 16,000 of its 2021

Pharma patents targeted by Biden in move to slash drug prices

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Wikipedia

hotspot

entertainment

New air purifier tech could be key to improving indoor air quality

Texas Department of Public Safety speaks out on migrant abuse allegations

Apple is now the first public company to be valued at $3 trillion

Patients' immediate access to test results puts radiologists in a bind

23andMe had bad news about my health. I wish a person had delivered it

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Trump demands the U.S. pay no more for drugs than other countries … again

Spinal cord stimulation reduces pain in amputees, study finds

How to save PrEP access — and even expand it

Study identifies new proteins linked to dementia risk 25 years later

leisure time

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Spinal cord stimulation reduces pain in amputees, study finds

After sickle

In diabetes hearing, Sanders takes on a new foe: food makers

Chemotherapy shortages won’t get better under Biden’s latest plan

Roche to buy Carmot Therapeutics, developer of obesity drugs

leisure time

hotspot

hotspot

hotspot